Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients

Hemodialysis International

Volumn 15, Issue 3, 2011, Pages 366-373

  Koc, Mehmet ^a   Dogan, Cengiz ^b   Arinsoy, Turgay ^b   Tonbul, Zeki ^b   Ayli, Deniz ^b   Cirit, Mustafa ^b   Sever, Mehmet Sukru ^b   Yilmaz, Mehmet Emin ^b   Unsal, Abdulkadir ^b   Suleymanlar, Gultekin ^b   Ok, Ercan ^b   Basci, Ali ^b   Yildiz, Alaatin ^b,c  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Fresenius Medical Care   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anemia; Erythropoietin resistance; Hemodialysis; HsCRP; Inflammation; Statin

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; ERYTHROPOIETIN; ERYTHROPOIETIN STIMULATING AGENT; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DATA BASE; DIASTOLIC BLOOD PRESSURE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMATOPOIESIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY FAILURE; PHOSPHATE BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TURKEY (REPUBLIC);

ADULT; AGED; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 79959941608     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00547.x     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32:S112-S119.
2. Parfrey PS. Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000; 15 (Suppl 5):58-68.
3. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002; 13 (Suppl 1):S28-S36.
4. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55:648-658.
5. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17:1684-1688.
6. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35:469-476.
7. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009; 119:671-679.
8. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17:S231-S235.
9. Indolfi C, Cioppa A, Stabile E, et al. Effects of hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000; 35:214-221.
10. Corpataux JM, Naik J, Porter KE, London NJ. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J Surg Res. 2005; 129:52-56.
11. Buemi M, Senatore M, Corica F, et al. Are there potential non-lipid-lowering uses of statins in the kidney? Nephron. 2001; 89:363-368.
12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352:29-38.
13. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352:20-28.
14. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42:1206-1252.
15. Pereira BJ. Cytokine production in patients on dialysis. Blood Purif. 1995; 13:135-146.
16. Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: Inadequate response to epoetin. Nephrol Dial Transplant. 2000; 15 (Suppl 4):43-50.
17. Barany P, Divino Filho JC, Bergstrom J. High c-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997; 29:565-568.
18. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J. 2001; 47:82-85.
19. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant. 2002; 17 (Suppl 1):53-59.
20. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33:63-72.
21. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol. 2003; 14:1776-1784.
22. Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998; 54:1337-1343.
23. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395-1407.
24. Solomon SD, Uno H, Lewis EF, et al. Trial to reduce cardiovascular events with aranesp therapy (TREAT) investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363:1146-1155.
25. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1{beta} receptor antagonist reduces ỳnflammation in hemodialysis patients. J Am Soc Nephrol. 2011; 22:437-442.
26. Rocco MV, Paranandi L, Burrowes JD, et al. Nutritional status in the hemo study cohort at baseline. Hemodialysis. Am J Kidney Dis. 2002; 39:245-256.
27. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55:1899-1911.
28. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987; 79:1635-1641.
29. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21:991-998.
30. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238-248.